Figure 7.

LTX-315-based local immunotherapy can be optimized by pre-sensitization of the tumor bed with low dosing of anti-CTLA4 mAb. (a) Experimental setting with bilateral tumor inoculations. Scheduling and routing of mAbs and LTX-315 as detailed in Materials and Methods section. s.c., subcutaneous; p.t., peritumoral; i.t., intratumoral. (b and c) Tumor sizes (upper panels) as well as percentages of complete tumor eradication (lower panels) at killing in the ipsilateral (treated, b) or contralateral (untreated, c) sarcoma in the context of local delivery of the immune checkpoint-targeting mAb (anti-CTLA4: 50 μg/mouse, two injections) or isotype control mAb injected before LTX-315. (d) Kaplan–Meier curves are depicted in the panel (combined data from two experiments). In all graphs, two experiments comprising 7–9 mice per group are shown. One-way ANOVA followed by Tukey's test: *P<0.05, **P<0.01, ***P<0.001; NS, not significant. Comparison of Kaplan–Meier survival curves were performed using the log-rank Mantel–Cox test: *P<0.05, ***P<0.001, ****P<0.0001; NS, not significant